American-British venture primed for face off with killer Sepsis

New, simple point-of-care technology will save lives through faster diagnosis and treatment of bacterial diseases.

Timely treatment for Sepsis and other serious conditions such as Urinary Tract Infections (UTIs) is essential for preventing a life-changing catastrophe in patient health, even death.

Currently it takes two to three days in medical practice to test and prescribe the right antibiotic to combat these serious infections. Now, a revolutionary new test and treatment process from an Anglo-American venture - Load&Go LLC, USA and Detect&Treat Ltd, UK - has reduced the turnaround time to less than 60 minutes.

Sepsis causes 11 million deaths globally every year (Sepsis Trust UK) while NHS England states that it "claims more lives than lung cancer and is the second biggest killer after cardiovascular disease."

Dr Ron Turner FIBMS PhD is founder and managing director of both companies, the small American-British medical diagnostic enterprise being focused on the manufacture and provision of reagent technologies in the human and veterinary Point of Care markets.

As Dr Turner explains, favourable trials and clinical evaluations* of this cost-effective instrument and reagent technology have been carried out across three continents - US, Europe and India - over the past four years. "It is a first in its field, is easy and simple to use and provides quantitative high sensitivity, high specificity results to the physician at the Point of Care in under an hour instead of days, the current standard," he says. What's more, clinical evaluation data on Sepsis patients will be available soon. The patented reagent technology has now been simplified for use at the Point of Care with the use of a small, cost-effective Point of Care instrument.

The joint enterprise has patents for the diagnostic reagent technology in the USA, Europe (UK) and Canada. Early in 2025 it will be launching, in conjunction with an India-based partner, an automated Point of Care platform, with applications (human and veterinary) for detection and treatment of Sepsis (whole blood), Urinary Tract Infection (UTI), Pleural fluid and Abdominal fluid.

Dr Turner and his team's work have already come to the notice of Lee Anderson MP for Ashfield in the UK and an avid campaigner on Sepsis. The technology has also caught the attention of the UK Sepsis Trust, medical representatives of whom Dr Turner is to have discussions with later this month but as one commented ahead of the meeting: "This sounds like an interesting advancement in rapid bacterial detection and antibiotic selection."

As with many new inventions and discoveries Dr Turner adds that he's urgently seeking the right investors to assist in developing the procedures involved and bring it onto the market. He explains: "On the funding side, there are two possibilities. Either a direct business sponsor (lump sum), grant money or several investors under an Advanced Subscription Agreement (ASA) with shares being issued. Of course, the sooner all this takes place, the sooner we can get down to the business of helping to save lives."

Dr Turner concludes: "This is an exciting development and addition to our Application portfolio. Initial data indicates the technology works well on whole blood samples. Clinical evaluations will be set up very soon to generate data on the Sepsis application."

*Clinical evaluations on UTI patients (human) produced: Detection (Test 1, n=249): Sensitivity of 97.1%, Specificity of 92.0%. Treatment: Antibiotic susceptibility/resistance (Test 2, n=82), Sensitivity of 94.0%, Specificity of 91.0%.

Detect&Treat LLC

USA: 1801 Rutherford Road, Building 1, Suite 117B, Greenville, South Carolina SC 29609.

Detect&Treat Ltd

UK: 19 Cotterall Court, Norwich, Norfolk NR5 9AX

Joint website via: www.detectandtreat.com

Media Contact Details:
Dr Ron Turner, Managing Director
Phone: +44 (0)7562 164595
Email: rontloadandgo@gmail.com

About Load&Go LLC and Detect&Treat Ltd:

The joint businesses were set up to commercialise Dr Turner's patented technology and seek prospects who might purchase the IP and/or invest with a view to a significant return on that investment.

The American-British enterprise is also working with an India-based diagnostic company who have designed and developed a simple, automated, cost-effective Microfluidic platform for use at the Point of Care.

About Dr Ron Turner:

Having worked in NHS Clinical Laboratories, he moved into the private sector, running and building Clinical Laboratories (USA and UK), before producing the technology that provides quantitative detection of bacterial infection (Test 1) and a quantitative antibiotic susceptibility/resistance (Test 2) on positive samples utilising bacterial-ATP bioluminescent signal output (based on % kill rate).

After generating data in two UK Medical Centres (data published), Dr Turner then worked with the India-based company to produce a simple, automated instrument platform for use at the Point of Care - Clinical Evaluation data on technology applications will now be generated to support the company claims.

A keen sports fan and keep fit enthusiast, he currently lives in Norwich, UK, close to his alma mater, the University of East Anglia (UEA).

This release was published on openPR.